Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors
- 1 April 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (7), 2128-2135
- https://doi.org/10.1158/1078-0432.ccr-06-2779
Abstract
Purpose: A fully human monoclonal antibody to anti–αv integrins (CNTO 95) has been shown to inhibit angiogenesis and tumor growth in preclinical studies. We assessed the safety and pharmacokinetics of CNTO 95 in patients with advanced refractory solid tumors. Experimental Design: In this phase I trial, CNTO 95 (0.1, 0.3, 1.0, 3.0, and 10.0 mg/kg) was infused on days 0, 28, 35, and 42, and clinical assessments, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and [18F]-2-fluorodeoxyglucose positron emission tomography (FDG-PET) were done. Patients achieving stable disease or better were eligible for extended dosing every 3 weeks for up to 12 months. Results: Among the 24 enrolled patients, CNTO 95 was associated with one episode of grade III and four episodes of grade II infusion-related fever (all responded to acetaminophen). Of the six patients who received extended dosing, one patient (10.0 mg/kg), with cutaneous angiosarcoma, had a 9-month partial response. Pre- and post-treatment lesion biopsies confirmed tumor cell αv integrin expression, as well as CNTO 95 penetration of the tumor and localization to tumor cells in association with reduced bcl-2 expression. A lesion in one patient (10.0 mg/kg) with stable ovarian carcinosarcoma was no longer detectable by FDG-PET by day 49. Exposure to CNTO 95 seemed to increase in a greater-than-dose-proportional manner; dose-dependent mean half-life ranged from 0.26 to 6.7 days. Conclusions: CNTO 95 was generally well tolerated. Six patients received extended therapy, including one patient with a prolonged response. Biopsy data confirmed tumor localization and pharmacodynamic activity.Keywords
This publication has 36 references indexed in Scilit:
- Experimentally‐derived functional form for a population‐averaged high‐temporal‐resolution arterial input function for dynamic contrast‐enhanced MRIMagnetic Resonance in Medicine, 2006
- Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor PerfusionClinical Cancer Research, 2005
- Integrin signalling during tumour progressionNature Reviews Molecular Cell Biology, 2004
- CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivoInternational Journal of Cancer, 2004
- Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumoursEuropean Journal Of Cancer, 2003
- A Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (antiαvβ3) Antibody in Patients with Metastatic CancerCancer Biotherapy & Radiopharmaceuticals, 2001
- Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an αv Integrin AntagonistNeurosurgery, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vesselsCell, 1994
- Requirement of Vascular Integrin α v β 3 for AngiogenesisScience, 1994